SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

24 May 2022 Evaluate
The sales for the March 2022 quarter moved down to Rs. 4556.57 millions as compared to Rs. 6335.99 millions during the year-ago period.The Net Profit of the company reported a remarkable increase of 317.07% to Rs. 2005.04  millions  from Rs. 480.75 millions in previous same quarter.Operating Profit reported a sharp decline to 1026.63 millions from 1113.29 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 4556.57 6335.99 -28.08 19790.03 18575.66 6.54 19790.03 18575.66 6.54
Other Income 848.29 233.06 263.98 1234.85 889.96 38.75 1234.85 889.96 38.75
PBIDT 1026.63 1113.29 -7.78 2001.15 2763.16 -27.58 2001.15 2763.16 -27.58
Interest 215.47 179.07 20.33 742.41 653.39 13.62 742.41 653.39 13.62
PBDT 811.16 934.22 -13.17 1258.74 2109.77 -40.34 1258.74 2109.77 -40.34
Depreciation 244.09 247.27 -1.29 1043.66 993.42 5.06 1043.66 993.42 5.06
PBT 567.07 686.95 -17.45 215.08 1116.35 -80.73 215.08 1116.35 -80.73
TAX -1437.97 206.20 -797.37 -1586.80 333.95 -575.16 -1586.80 333.95 -575.16
Deferred Tax 146.74 71.38 105.58 -2.09 123.77 -101.69 -2.09 123.77 -101.69
PAT 2005.04 480.75 317.07 1801.88 782.40 130.30 1801.88 782.40 130.30
Equity 897.90 896.80 0.12 897.90 896.80 0.12 897.90 896.80 0.12
PBIDTM(%) 22.53 17.57 28.23 10.11 14.88 -32.02 10.11 14.88 -32.02

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×